Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT05457465
PHASE2
Assessing the Impact of Cannabidiol for Anxiety and Depression in Bipolar Disorder
Sponsor: Mclean Hospital
View on ClinicalTrials.gov
Summary
Preliminary data have suggested that cannabidiol (CBD) may have a number of clinical benefits, including anti-anxiety and antidepressant properties. This study is a pilot open-label clinical trial assessing a custom-formulated high-CBD product over the course of 4 weeks in patients with bipolar disorder who experience anxiety.
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
25
Start Date
2023-06-01
Completion Date
2026-12
Last Updated
2026-03-30
Healthy Volunteers
No
Conditions
Interventions
DRUG
Cannabidiol
Custom formulation of a hemp-derived, high-CBD product that contains no THC.
Locations (1)
McLean Hospital
Belmont, Massachusetts, United States